Microbial Modulation of Bile Acid in Cardiovascular Disease: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Tess Yntema
,
Debby P. Y. Koonen
,
Folkert Kuipers

Bile acids represent a class of cholesterol derivatives that is essential for intestinal absorption of lipids and fat-soluble vitamins, plays an important role in cholesterol turnover and, as more recently discovered, acts as a group of signaling molecules that exerts hormonal functions throughout the body.

  • gut microbiota
  • bile acids
  • cardiovascular disease
  • atherosclerosis

1. Bile Acids Are Synthesized by the Liver and Extensively Metabolized by the Microbiota

Bile acids (BAs) are amphipathic cholesterol derivates, characterized by one or more hydroxyl groups at their steroid nucleus (in mammals, commonly at positions 3, 7, and/or 12) and a shortened side chain bearing a carboxylic acid group [1] (Figure 1A). BAs are exclusively synthesized in hepatocytes in a process that involves a cascade of enzymatic steps in different compartments of the cell [2][3][4]. The products of this multi-step process are the so-called primary BAs, i.e., cholic acid (CA) and chenodeoxycholic acid (CDCA) in humans, which are products of the well-established “classical” or “alternative” pathways [5].
Nutrients 15 01850 g001
Figure 1. (A) Structural formula of bile acid. (B) Hepatic BA synthesis, enterohepatic circulation, and microbial BA modifications in the human body. BA = bile acid; CA = cholic acid; CDCA = chenodeoxycholic acid; DCA = deoxycholic acid; UDCA = ursodeoxycholic acid; LCA = lithocholic acid; TCA = taurocholic acid; GCA = glycocholic acid; C = cholesterol; BSEP = bile salt-export pump; NTCP = Na+-taurocholic acid co-transporting polypeptide; ASBT = apical sodium-dependent BA transporter; Ostα/β = organic solute transporter α/β; BSH = bile salt hydrolases; HSDH = hydroxysteroid dehydrogenase; bai = BA inducible genes. This illustration was created with Biorender.com (accessed on 1 February 2023).
The first step of the classical pathway is catalyzed by the rate-controlling enzyme cytochrome P450 cholesterol 7α-hydroxylase (CYP7A1), which yields 7α-hydroxycholesterol [2][6] (Figure 1B). The alternative pathway is initiated by sterol 27α-hydroxylase (CYP27A1), and further processed by oxysterol 7α-hydrolase (CYP7B1) [6]. The 7α-hydroxylated intermediates from both the classical and alternative pathway undergo several sterol ring modifications, as well as side chain oxidation and shortening, leading to the production of CDCA [5][6]. In addition, the classical pathway also generates CA, which involves the activity of sterol 12α-hydroxylase (CYP8B1) [7]. Of note, rodents produce additional forms of primary BAs in the liver—α- and β muricholic acids (MCAs) and ursodeoxycholic acid (UDCA)—which are derived from CDCA by mouse/rat-specific cytochrome P450 2C70 (Cyp2c70) [5][8].
Primary BAs are conjugated with either taurine or glycine at the C24 position, which allows for their active secretion into the bile and decreases their pKa, and hence prevents passive reabsorption in the upper intestine [4]. BAs are secreted into the bile canaliculi by the bile salt-export pump (BSEP) and stored in the gallbladder in high mM range [5][9] (Figure 1B).
Upon meal intake, cephalic-phase-induced cholecystokinin secretion from the duodenum stimulates gallbladder contraction, leading to the discharge of stored BAs into the intestine [4]. In the intestinal lumen, BAs solubilize lipids, including cholesterol, and fat-soluble vitamins. Most primary BAs are actively reabsorbed in the ileum by the apical sodium-dependent BA transporter (ASBT) [4]. A small proportion of BAs escape uptake and reach the colon, where the gut microbiota can convert primary into secondary BAs (lithocholic acid (LCA) and deoxycholic acid (DCA)), a process that involves three major groups of bacterial enzymes (discussed in the subsequent section) [3]. Unconjugated secondary BAs are relatively hydrophobic and can thus be passively reabsorbed from the colon [10]. Most BAs (95%) are reabsorbed in the ileum or colon, and via the portal vein they are delivered back to the liver, whereafter they are taken up by Na+-taurocholic acid co-transporting polypeptide (NTCP), in order to finalize a process called the enterohepatic circulation. In the liver, unconjugated primary and secondary BAs are re-conjugated and secreted into bile. Only a minor amount (~5%) of BAs, which are not taken up in the ileum or colon, are excreted in feces per cycle [10]. This loss of BAs is compensated by the de novo synthesis of BAs in the liver to maintain the size of the circulating BA pool [10].
A relatively small fraction of BAs escape first pass clearance by the liver and flow into the systemic circulation, with concentrations in the µM range [9]. From the peripheral circulation, BAs can reach multiple organs, including adipose tissue, muscle, and the heart [11][12]. BAs exert hormone-like functions by acting as signaling molecules and activate several BARs, i.e., nuclear receptors—farnesoid X receptor (FXR), vitamin D receptor (VDR), pregnane R receptor (PXR)—and membrane-bound receptors—Takeda G protein-coupled receptor (TGR5) and muscarinic receptors (MRs). Through these actions, BAs regulate their own homeostasis, as well as lipid and glucose metabolism, intestinal barrier function, cardiovascular functions, and inflammation [11][13][14]. Importantly, different BA species have dissimilar affinities for the activation of BARs (FXR: CDCA > LCA = DCA > CA; TGR5: LCA > DCA > CDCA > CA; VDR: LCA; PXR: LCA = CDCA = DCA = CA) [9][15]. Differences in BA pool composition, which are prominent across individuals [16], will thus affect BA signaling in a personalized manner.

2. Bacteria Involved in Bile Acid Metabolism

The three major groups of bacterial enzymes—bile salt hydrolases (BSHs), hydroxysteroid dehydrogenases (HSDHs), and bile-acid-inducible (bai) genes—are responsible for the generation of secondary BAs in the colon, leading to a major increase of the diversity of the BA pool. The major structural modifications include deconjugation, which is an obligatory first step; oxidation of hydroxy groups at the C3, C7, and C12 position; and 7α/β-dehydroxylation [3][4]. In addition, (7α/β, 3α/β) isomerization- and (5-H α/β) epimerization modifications give rise to UDCA and iso- and allo-BAs, respectively [5].
BSHs catalyze the deconjugation of the N-acylamide bond between primary BAs and taurine or glycine at the C24 position [4]. BSHs have been identified in several microbial genera, including Bifidobacterium [9][17], Clostridium [9][18], Enterococcus [9], Listeria [9][19][20], Lactobacillus [9][21][22], and Bacteroides [23]. Recently, computational analyses have shown that the human gut microbiota contains 591 intestinal bacterial strains within 117 genera with BSHs sequences [24]. BSHs, encompass seven [25] or eight sub-groups [24], showing differences in deconjugation ability. BSH-T3 shows the highest enzyme and deconjugation activity and is only found in Lactobacillus [24]. Recently, research has shown that, after deconjugation, the gut bacteria can also mediate the conjugation of the CA backbone with the amino acids phenylalanine, tyrosine, or leucine [26]. The microbial enzyme responsible for these BA modifications remains unknown. Interestingly, these amino acid BA conjugates are found in humans and are enriched in patients with inflammatory bowel disease or cystic fibrosis [26].
The second major group of bacterial enzymes are HSDHs, which oxidize and epimerize C3, C7, and C12 hydroxy groups of BAs. HSDH enzymes have been identified in the microbial genera Blautia (3α), Clostridium (3-, 7-, 12α), Eggerthella (3-, 12α), Mediterraneibacter (3α), Bacteroides (7α), Collinsella (7α), and Eubacterium (7α) [9]. Epimerization of hydroxy groups leads to a reversible change from the α to the β configuration, generating stable oxo-BAs as intermediates [4]. The reaction depends, in part, on the redox potential of the environment. For example, oxo-BAs are more present at the mucosal surface, where the redox potential is high, whereas less oxo-BAs are present in the lumen of the large intestine, where the redox potential is low [3]. Interestingly, the production of 12-oxoCDCA may reduce the formation of secondary BA DCA [27], which has been implicated in liver [28] and colon cancer [29], cholesterol gallstone formation [30], and CVD [31].
Bacteria that carry the bai operon produce enzymes that carry out 7-α/β dihydroxylation, resulting in the major secondary BAs DCA and LCA. Surprisingly, this metabolic pathway is only found in 0.0001% of colonic gut microbiota, belonging to the genera Clostridium [3][4][32]. Moreover, 7-α/β dehydroxylation only takes place after deconjugation, implicating a functional interplay between deconjugation and dehydroxylation [3].
Thus, the gut microbiota is responsible for diversifying the BA pool. This strongly affects BA signaling, as BAs have different affinities towards BARs [10]. Importantly, the regulation between the gut microbiota and BAs is reciprocal, meaning that BAs can also modulate the gut microbiota either by direct or indirect effects. For example, BAs can disrupt bacterial membranes or bind to intestinal FXR, promoting the expression of antimicrobial agents [33]. Moreover, conjugated BAs play an important role in the prevention of bacterial overgrowth in the proximal small intestine, which is relatively devoid of microbes under normal conditions [34]. Studies have shown that replenishing intestinal BA concentrations in BA-deficient rats abolished bacterial overgrowth in the small intestine [34]. On the other hand, bacteria that inhabit the intestinal tract must have specific resistance mechanisms to protect themselves against bile [35]. For example, Lactobacillus and Bifidobacterium produce proteins that are devoted to the efflux of BAs [35].
Of note, gut bacteria can also directly metabolize cholesterol in the intestine via dehydrogenase activity encoded by intestinal sterol metabolism A (ismA) genes, producing cholestanone and coprostanol [36]. These genes are found in the human gut microbiota in geographically diverse human cohorts and show a negative correlation with circulating cholesterol levels [36]. In addition, recent studies highlight the bacterial potential to sulfonate cholesterol and related steroids in the gut. The sulfotransferase enzyme is identified in the microbial species Bacteroides thetaiotaomicron [37][38]. The new (direct) lipid-metabolizing functions of the gut microbiota, which was originally thought to be performed by host enzymes, represent a great breakthrough in the understanding of cholesterol homeostasis.

3. Gut Microbiota Signatures in Cardiovascular Disease

Since the late 1980s, researchers have implicated a role of bacteria in atherogenesis [39]. In these early studies, the bacterium Chlamydia pneumoniae was associated with CAD and myocardial infarction. A few years later, bacterial DNA from many other bacteria genera/species were found in human atherosclerotic plaques [40][41][42], whereas healthy tissue (e.g., non-transplanted hearts) does not contain bacterial DNA [43]. Bacterial DNA has also been linked to inflammation, as the amount of bacterial DNA was found to correlate with the number of leukocytes in the plaque [40]. This suggests that the underlying pathophysiology of atherosclerosis may involve bacterial activation of the immune system. In addition, bacteria originating from the gut and the oral cavity matched with bacterial DNA present in atherosclerotic plaques and correlated with disease biomarkers [40]. Thus, the re-allocation of bacteria from the intestinal tract to the heart may contribute to disease development, which has sparked interest to evaluate the role of the gut microbiota in CVD.
In general, gut microbiota diversity has been found to negatively correlate with risk factors of atherosclerosis, such as obesity, hyperinsulinemia, hypertension, and dyslipidemia [44][45][46]. However, others have demonstrated that alpha diversity was either not different or increased in atherosclerosis patients compared with the controls [47][48][49][50][51]. These discrepancies could be due to limitations in the respective studies, such as omitting important confounders in their analyses (e.g., age, sex, and BMI) or assessing diversity with an estimation-based method (Chao1) [47]. Moreover, the temporal dynamics and intra- and interindividual heterogeneity of the gut microbiota underscores the difficulty in studying and comparing cross-sectional studies. Rodent models (especially germ-free models), which are more experimentally controlled, represent an invaluable tool for studying microbe–host interactions in the context of CVD.

4. Altered Bile Acid Metabolism in Cardiovascular Disease

Examining the composition of the gut microbiota at one single point in time ignores the complex nature of the gut microbiota as an ecosystem. Investigating functional shifts of the gut microbiota, including changes in gut-derived metabolites, helps to identify measurable read-outs of bacterial functions in health and disease. BAs might be a relevant gut metabolite in relation to CVD, despite controversy across studies [52][53][54][55]. Lower plasma BA levels have been reported in CVD [52][53]. Low serum BAs appeared to be independently associated with the presence and severity of CAD, especially for the presence of myocardial infarction (MI) [53]. These results were largely confirmed by Nguyen et al., although serum BA concentrations in both the control and CAD patients were lower compared with the previous study [52]. The latter study also observed doubled serum BAs in patients receiving statin therapy, suggesting that serum BAs levels are amendable by statin administration in CAD patients. Statins are a commonly described drug to lower cholesterol via the inhibition of β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase, the rate limiting enzyme in the cholesterol biosynthesis pathway [56]. Moreover, glyco-CDCA was two-fold higher in CAD patients [52] and, together with the total serum BAs, were predictors of CAD [52][53]. In contrast, a previous study comparing CAD and non-CAD patients did not demonstrate a significant association between serum BAs and CAD [54]. In addition, the total serum BAs are known to increase in patients with liver cirrhosis, which is associated with cardiac dysfunction [55]; total serum BAs are elevated up to 100 times the normal values in patients with cirrhotic cardiomyopathy [55], i.e., much more compared with CAD patients. Although inconsistency is found between studies, it appears that either low or extreme high serum BAs can be associated with CVD.
For zooming in on small-molecule metabolites in relation to CVD, untargeted metabolomics is a powerful tool to discover novel metabolites. Zhang et al. discovered that six metabolites were significantly altered in CAD patients [57]. LCA, together with 4-pyridocix acid and phosphatidylglycerol (20:3/2:0), showed the strongest positive correlation with CAD, defined as >80% stenosis in at least one artery. Of note, Chen et al. observed large inter-individual variability in plasma BA profiles in human obesity [16]. This variability suggests a more personalized approach to finding biomarkers and future therapeutic applications of BAs in CVD, although participants with recent cardiovascular events were excluded from this study [16]. Nevertheless, secondary BAs, i.e., DCA and LCA, were associated with diabetes and liver fat content, which are two risk factors of CVD, in these obese subjects.
In addition to plasma BAs, fecal bile acid excretion (BAE), which equals hepatic BA synthesis under steady state conditions, has also been associated with CAD [58][59][60]. CAD-patients were found to excrete less BAs, particularly DCA and LCA, compared with non-CAD controls [58][59][60]. A historical follow-up of 20 years showed that BAE was a significant independent parameter that predicted CAD in humans, in which BAE < 415 mg/day was associated with a higher long-term mortality due to CAD [60]. More specifically, 75% of the patients with BAE < 262.4/day developed a stroke relative to none of the patients with BAE > 622 mg/day [59]. BAE can thus serve as an interesting biomarker of CAD.
Thus, these studies provide evidence that measuring plasma and fecal BAs may aid in the assessment of the gut microbiota contributions to CVD. Understanding determinants of BA pool/metabolism and its reflection in CVD is important to rationalize their use as potential biomarkers and therapeutic targets.

5. Bile Acids as Mediators of Cardiovascular Disease Risk

In this section, the focus switches from association to causality regarding the potential roles of BAs in CVD. The multifaceted roles of BAs in lipid homeostasis, immunity, and heart function indicate the ability to mediate CVD, as discussed in the following sections (Figure 2).
Nutrients 15 01850 g002
Figure 2. Bile acid regulation in lipid and immune metabolism, and heart function. Mechanistic effects of BAs in different organs (heart/vasculature/circulation/colon/lamina propria) or cell types (cardiomyocyte, endothelial cell, vascular smooth muscle cell, immune cells, enterocyte) in relation to lipid and immune metabolism, and heart function. CM = cardiomyocyte; EC = endothelial cell; VSMC = vascular smooth muscle cell; Th17—T helper 17 cells; Treg = Regulatory T cells; FXR = farnesoid X receptor; VDR = vitamin D receptor; PXR = pregnane R receptor; NR4A1 = nuclear receptor 4A1; TGR5 = Takeda G protein-coupled receptor; MR = muscarinic receptor; S1RP2 = sphingosine 1-phosphate receptor 2; SR-A1 = Class A1 scavenger receptors; AT2R = angiotensin II receptor type 2; TLR2—toll-like receptor 2; NCX = Na+/Ca2+ exchange protein; BKCa = large conductance Ca2+-activated K+; ASBT = apical sodium-dependent bile acid transporter; BA = bile acid; UDCA = ursodeoxycholic acid; (T/G)DCA = (tauro/glycol)deoxycholic acid; (T)LCA = Taurolithocholic acid; TCA = Taurocholic acid; CDCA = chenodeoxycholic acid; NF-κB = nuclear factor kappa B; PTP = Mitochondrial permeability transition pore; PLTP = phospholipid transfer protein; ET = endothelin-1; NO = nitric oxide; ROS = reactive oxygen species; PPARα = peroxisome proliferator-activated receptor alpha; SREBP1c = sterol regulatory element binding protein 1c; CYP7A1 = cytochrome P450 7A1; CYP39A1 = cytochrome P450 39A1; ApoA-IV = Apolipoprotein A-IV; NLRP3/4 = NLR family pyrin; FOXP3 = forkhead box P3; SMPD3 = Sphingomyelin Phosphodiesterase 3; SERCA2B = Sarcoendoplasmic reticulum calcium ATPase 2b; FGF15/19 = fibroblast growth factor 15/19; Ang1 = angiopoietin 1; iNOS = nitric oxide synthase; IL = interleukin; TJ = tight junction; * = hydrophobic bile acid pool; # = hydrophilic bile acid pool. This illustration was created with Biorender.com.

5.1. Regulation of Lipid Metabolism

Recent studies have shown that the elevation of plasma triglycerides (TG) comprises the major lipid abnormality in patients with atherosclerosis, changing the focus from LDL cholesterol to TG as being causal in atherosclerosis [61]. Interestingly, BAs appear to display beneficial effects in hypertriglyceridemia [62]. BA activation of the FXR-SHP pathway interferes with the regulation of fatty acid biosynthesis genes, mediated by the liver X receptor (LXR) and sterol regulatory element binding protein 1c (SREBP-1c) [62]. Feeding mice for 8 weeks with 0.5% CA was associated with a reduction in hepatic SREBP-1c expression and its lipogenic target genes in mouse models [62]. It has been proposed that the rate of hepatic lipogenesis is a major determinant of very-low-density lipoprotein (VLDL)-TG production, although it has been reported that massive lipogenesis in obese ob/ob mice does not lead to increased VLDL production [63]. While SREBP controls fatty acid synthesis, peroxisome proliferator-activated receptor α (PPARα) promotes fatty acid β-oxidation [64][65][66]. Th activation of PPARα by fenofibrate reduced the plasma TG’s, adiposity, and atherosclerosis development in high-fat diet-fed Ldlr−/− mice [67][68]. Lipid accumulation in the aorta was prevented upon PPARα activation, probably by enhanced fatty oxidation. BAs can also induce PPARα via the activation of FXR [69].
In contrast with these beneficial effects in hypertriglyceridemia, BA activation of PXR, a well-known transcription regulator in the control of lipid metabolism [31][70], increased levels of total cholesterol, VLDL, and LDL; decreased high-density lipoprotein (HDL) levels; and increased atherosclerosis in ApoE−/− mice [71], while PXR deletion reduced atherosclerosis in ApoE−/− mice [72]. The genes involved in lipoprotein transport and cholesterol metabolism, including apolipoprotein A-IV (ApoA-IV), cytochrome P450 family 39 subfamily A member 1 (Cyp39a1), and cluster of differentiation 36 (Cd36), were affected upon PXR activation [71]. ApoA-IV and Cyp39a1 were down-regulated, whereas Cd36 was upregulated. Studies have indicated that CD36 plays an important role in atherosclerosis by mediating oxidized LDL (oxLDL) uptake by macrophages, leading to the formation of foam cells [73]. PXR activation in peritoneal macrophages led to increased Cd36 expression, which was consistent with increased lipid accumulation in these cells [71]. In addition, GUDCA was shown to inhibit macrophage foam cell formation by down-regulating scavenger receptor A1 gene expression, whereas Cd36 expression was not affected, implicating a different mode of action [74].
Of note, compensatory mechanisms preventing lipid accumulation in the circulation have been observed while directly targeting BA synthesis in CYP27A1/ApoE double-knockout (DKO) mice [31]. Zurkinden et al. showed that loss of the BA synthesis gene Cyp27a1 in ApoE−/− mice fed a Western-type diet (WD) was associated with an upregulation of Cyp7a1 and cytochrome P450 3A1 (Cyp3a1), resulting in increased BA synthesis and excretion (i.e., accelerated cholesterol turnover), and protection against atherosclerosis [75]. In this study, they also observed differential cardiovascular outcomes of CA and CDCA feeding, in addition to the WD. Despite the observation that both feeding regimes led to reduced Cyp7a1 and Cyp3a1 expression, only CA-WD resulted in a strong increase in atherosclerosis, together with increased LDL and reduced HDL in the serum, increased intestinal absorption of cholesterol, and decreased faecal cholesterol output [75]. Although in humans CDCA is a more potent FXR agonist than CA, in rodents, FXR is mostly activated by CA as CDCA is rapidly converted in MCAs (FXR antagonists) [76]. Macrophage FXR activation by CA takes part in reverse cholesterol transport and reduces the HDL efflux [75]. In addition, the hydrophilic MCAs in the BA pool in CDCA-WD fed mice are likely responsible for the reduced cholesterol absorption [75], as the 12α-OH group of C7 appears to be essential for efficient cholesterol uptake by enterocytes [77].
Similar to BA sequestration, directly blocking intestinal BA absorption also affects BA synthesis. Targeting ASBT leads to the increased expression of BA synthesis genes and HMG-CoA reductase in ApoE−/− mice [78]. To fuel the liver with additional cholesterol, hepatocytes increase both the de novo synthesis and expression of the cell surface LDL receptors, which results in reduced plasma cholesterol and less prominent aortic lesions.
FXR and TGR5 are both expressed in the vasculature. Whereas FXR is found in vascular smooth muscle cells (VSMCs) and endothelial cells of the vascular wall [79] (and possibly in macrophages [80]), TGR5 is expressed on the surface of macrophages [81], which are present in atherosclerotic plaque. Studies have shown that the activation of FXR in rat and human VSMCs reduces migration and inflammation [82], and affects lipid metabolism [79]; the latter particularly via phospholipid transfer protein (PLTP), an important regulator of reverse cholesterol transport. Moreover, FXR activation has been shown to mediate vasodilation in endothelial cells [83] and TGR5 activation to reduce inflammatory responses in macrophages [84].
Studies have evaluated the effect of TGR5 and/or FXR activation on atherogenesis [84][85]. The activation of TGR5 by INT-777 attenuated atherosclerosis development in Ldlr−/− mice. INT-777 treatment led to reduced macrophage lipid loading and pro-inflammatory cytokine production, an effect mediated by altered cAMP-signalling and nuclear factor-κB (NF-kB) inhibition [84]. In the absence of TGR5, these anti-atherosclerotic effects were abolished [84]. Similarly, simultaneous activation of FXR and TGR5 by the dual agonist INT-767 in Ldlr−/− mice reduced atherosclerosis via anti-inflammatory and lipid-lowering effects [85]. FXR deficiency alone completely blocked the lipid-lowering effects of INT-767: this was not found in TGR5-deficient mice. Interestingly, both FXR- and TGR5-deficient mice show reduced atherosclerosis and aortic inflammation upon INT-767 administration [85].
Thus, the anti-atherosclerotic effect of FXR and TGR5 activation is driven by inflammation, and the loss of one receptor is compensated by the other. Moreover, these anti-atherosclerotic effects of INT-767 were abolished by the dual deficiency of FXR and TGR5 in Ldlr−/− mice [85]. In addition, Jadhav et al. found that INT-767 induced thermogenesis genes and reduced hepatic de novo lipogenesis genes, suggesting an additional role in energy homeostasis on top of the anti-atherosclerotic effects of this compound [86].
Intriguingly, both the deficiency and activation of FXR leads to similar results in atherosclerosis mouse models. FXR loss of function results in a decreased atherosclerotic plaque surface in Ldlr−/− and ApoE−/− mice [87][88]. Although the serum cholesterol levels were reduced, the TGs were elevated in these models. Peritoneal macrophages showed a reduced Cd36 gene expression and decreased lipid accumulation in FXR-LDLR DKO mice [88]. This suggests an indirect effect of FXR on macrophages. FXR activation also showed an atheroprotective effect in atherosclerosis models, which was in part the result of an improved lipid profile [85][86][89][90]. TG-lowering effects can be controlled by FXR-induced lipoprotein lipase and SREPB-1c activity [89]. Other anti-atherosclerotic effects could be the result of increased fecal cholesterol excretion and macrophage reverse cholesterol transport due to reduced BA pool size and composition [90]. Thus, both loss of function and activation of FXR attenuates atherogenesis in mice, which complicates the interpretation of these results.
Recent research has demonstrated that patients with hypercholesterolemia have elevated fibroblast growth factor 19 (FGF19), which is positively correlated with pro-atherogenic ceramide levels [91]. Intestinal FXR activation releases FGF19 (or fibroblast growth factor 15 (FGF15) in rodents) in the ileum, which is a negative regulator of hepatic BA synthesis. Intestinal FXR-deficient ApoE−/− mice showed decreased atherosclerotic lesions in the aorta and heart, and reduced serum levels of ceramides after high-cholesterol diet feeding [91]. The enzyme sphingomyelin phosphodiesterase 3 (SMPD3) was identified as an intestinal FXR target, which is involved in ceramide synthesis. The overexpression of SMPD3 eliminated the anti-atherosclerotic effects in intestinal FXR-deficient ApoE−/− mice [91].
Thus, BAs play an important role in lipid metabolism, as BAs affect BA and lipid synthesis, absorption, and excretion, but are also involved in foam cell formation and ceramide synthesis, which are both associated with CVD. Although it is not always clear whether the lipid-lowering (anti-atherosclerotic) effects of BAs are caused by direct or indirect effects of BA signalling, BAs represent an interesting therapeutic target for CVD.

5.2. Regulation of Immune Functions by Secondary Bile Acids

Inflammation plays a central role in CVD, involving both the innate and adaptive immune systems [92][93][94][95][96][97][98][99]. Alterations in the gut microbiota are associated with impaired gut integrity, leading to increased leakage of microbiota-derived LPS, which promotes systemic inflammation [92]. Targeting innate immunity with antibodies against interleukin-1 beta (IL-1β) led to reduced recurrent cardiovascular events in patients with previous myocardial infarction, independent of lipid lowering [100], suggesting that CVD is driven by inflammation. Interestingly, among the continuously growing list of metabolites regulating the immune system, secondary BAs are recognized to possess immuno-regulatory properties that affect CVD development [101].
FXR signalling is evidently involved in the maintenance of intestinal integrity and the regulation of inflammatory processes. For example, intestinal FXR activation has been shown to protect mice from intestinal inflammation through the downregulation of key pro-inflammatory cytokines [102], which are known to increase the permeability of the intestinal epithelial monolayer [102][103]. A different study showed that the genes encoding tight junction proteins, zonulin-1 and occludin, were increased upon FXR activation in a cirrhotic rat model [104]. In addition, FXR has been shown to induce the expression of genes such as angiopoietin 1 (Ang1), inducible NO synthase (iNOS), and interleukin-18 (Il-18), which show anti-microbial effects and protect the mucosal intestinal barrier in mice [105]. VDR is also involved in maintaining gut integrity and can be activated by LCA and iso-LCA [15][106][107]. The activation of VDR by LCA showed a protective effect on tumor necrosis factor alpha (TNFα)-induced injury of intestinal barrier function in Caco-2 cells, possibly through the NFκB signalling pathway [106]. Moreover, cell experiments demonstrated that LCA can induce adhesion molecule expression in endothelial cells through the activation of reactive oxygen species formation, NF-κB, and p38 mitogen-activated protein kinase (MAPK) signalling [108]. Increased surface adhesion molecules can attract immune cells to the vascular wall. Controversially, studies have shown anti-inflammatory effects upon VDR activation in CVD [31][109][110][111].
On the contrary, in vivo and in vitro studies have shown that the prolonged presence of excess DCA can reduce gut barrier function and promote intestinal inflammation [112]. DCA may serve as an endogenous danger-associated molecular pattern (DAMP) and activate inflammasome NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), a cytosolic multiprotein of the innate immune system, which promotes the secretion of pro-inflammatory cytokines [113]. DCA binds to the sphingosine-1-phosphate receptor 2 (S1PR2) in macrophages that mediates NLRP3 activation [113]. Moreover, Wang et al. found that HFD-induced dysbiosis promotes DCA production, leading to increased pro-inflammatory colonic macrophage infiltration in mice [114]. DCA dose-dependently promoted M1 macrophage polarization and cytokine production via the NF-kB signalling pathway, partially through toll-like receptor 2 (TLR2) and muscarinic 2 receptor (M2R) activation.
TGR5 activation in CD4 T cells inhibits inflammation by regulating the recruitment of CD4 and CD8 T cells after myocardial infarction [115]. In line with this anti-inflammatory effect, the administration of TLCA led to NLRP3 inflammasome inhibition via the TGR5-cAMP-PKA axis in T cells and macrophages. PKA can induce the phosphorylation of NLRP3, thereby preventing the activation of the inflammasome [116]. Interestingly, SHP is a negative regulator of NLPR3 inflammasome activation and its deficiency showed increased pro-inflammatory cytokines in vivo, including Il-1β and Il-18 [117].
Similar to FXR and TGR5, VDR activation exhibits strong anti-inflammatory effects in macrophages [118][119][120]. VDR deletion increased foam cell formation from a lack of the VDR-sarcoendoplasmic reticulum calcium ATPase 2b (SERCA2b) interaction, causing activation of ER stress and the induction of CD36 and class A1 scavenger receptor (SR-A1) in the macrophages [118]. SERCA2b, is a critical enzyme that maintains ER calcium levels to optimize protein production and folding [118].
Accumulating evidence indicates that an altered microbiota can activate both the innate and adaptive immune system [121][122][123]. Western-type diet-induced dysbiosis [121] and microbes from CAD patients [122] was shown to modulate BA pool composition, worsen gut barrier permeability, and increase systemic and intestinal inflammation, likely by imbalanced T helper and T regulatory cells (Tregs) in the intestinal lamina propria. A higher ratio of retinoid-acid-related orphan receptor-γt (RORγt) T helper 17 cells to (Helios+) regulatory T cells was observed [121][122]. While transcription factor RORγt is required for the differentiation of pro-inflammatory Th17 cells, orchestrating intestinal inflammatory responses, Helios+ cells play a critical role in tissue repair, and in the maintenance of gut barrier function [124]. Chen et al. speculated that BAs and other oxysterols can serve as endogenous RORγt agonists, modulating different T cell subsets [121]. Indeed, fecal LCA is positively correlated with the Th17−Treg ratio in the intestinal lamina propria [122], suggesting that signals from the gut microbiota could drive the differentiation and maintenance of T cell subsets in the intestine. In addition, microbes from CAD patients led to increased reactive oxygen species generation and vascular stiffness in the aorta, probably caused by increased intestinal inflammation and worsened gut barrier permeability [125].
Follow-up studies have shown that derivates from LCA can modulate T cell subsets. While 3-oxoLCA inhibited the differentiation of Th17 through direct binding to RORγt [107][126], iso-alloLCA increased the differentiation of Tregs [107] in a nuclear hormone receptor Nur77-dependent manner [127], enhancing Forkhead Box P3 (FOXP3), a master regulator in the development and functioning of Tregs. Changing the BA pool by manipulating dietary and microbial factors confirmed the role of BAs in modulating FOXP3 Tregs in the colon [128]. The genetic ablation of BA enzymes in the bacteria reduced Tregs, which was resolved after restoring the BA content in the intestine. Moreover, a nutrient minimal diet lowered fecal deconjugated BAs and reduced Tregs in the colon, which was only restored by the administration of LCA/3-oxo-LCA [128]. Investigating different BA receptors in modulating colonic Treg cell populations demonstrated a major role of the BA-VDR pathway [128]. VDR is expressed in FOXP3 Tregs, but also in endothelial and dendritic cells in the colon [128]. The secondary BA isoDCA can increase FOXP3 Treg induction by acting on dendritic cells [129]. Dendritic cell FXR ablation led to increased Treg production, showing the same transcriptional profile compared to isoDCA induction [129]. The role of VDR in this process was not investigated. Interestingly, human VDR genetic variants could affect intestinal inflammation through controlling the Treg pool [130]. Forward genetics studies have observed polymorphisms in the VDR promotor, which controlled VDR expression and T cell activation [130]. The different activation status of VDR could affect intestinal inflammatory susceptibility through the improper control of Tregs in the colon, driving low-grade systemic inflammation [130].
Thus, both the innate and adaptive immune systems can be modulated by BA signalling, either by boosting or inhibiting inflammatory responses. Therefore, (indirectly) targeting BA metabolism to reduce systemic inflammation could be a new therapeutic opportunity for CVD.

5.3. Regulation of Heart Function

Studies have shown a direct role of BAs in features of heart and arteries (cardiovascular tissue). BAs appear to regulate cardiovascular function through the activation of BARs (FXR, TGR5, and VDR) and MRs, as well as through the interaction with ion channels in cardiovascular tissue [11]. This section summarizes BA signalling in relation to cardiovascular function.
FXR is highly expressed in the liver, kidney, and gastrointestinal tract, but is also expressed in heart tissue (i.e., cardiomyocytes and fibroblasts) and in the vasculature (i.e., endothelial and vascular smooth muscle cells) [79]. FXR activation results in cell-type specific responses [79][83][131][132][133][134]. FXR activation of isolated neonatal rat cardiomyocytes, either by natural (CDCA) or synthetic (GW4064) FXR activators, induced apoptosis [131]. Interestingly, increased Fxr expression was observed after myocardial ischaemia/reperfusion in mouse hearts, whereas both pharmacological inhibition or the genetic deletion of FXR reduced myocardial apoptosis, decreased infarct size, and improved the cardiac function of ischaemic hearts [131]. Hydrophilic UDCA was shown to protect the myocardium against reperfusion injury in rat hearts by blocking the opening of the cardiac mitochondrial permeability transition pore (PTP) during reperfusion of the heart [135].
Studies have also indicated a role of BAs in regulating vascular tension [83][134][136]. For example, activation of endothelial FXR led to downregulation of Endothelin-1 (Et-1) and Il-1 mRNA expression, both potent vasoconstrictive agents [83]. Additionally, FXR activation resulted in upregulation of endothelial nitric oxide synthase (eNOS) [134]. eNOS-derived nitric oxide (NO) has vasodilatory effects and plays an important role in vasomotor tone, VSMC proliferation, platelet aggregation, and the inhibition of lipid oxidation [137]. Mechanistic studies reported an FXR-responsive element in the eNOS promotor [134]. In vitro and in vivo studies demonstrated that, next to FXR, the activation of TGR5 also increased NO production in aortic endothelial cells, and reduced monocyte adhesion and the activation of NF-kB [136]. In addition, DCA treatment improved cardiac function by inhibiting Il-1β expression in the infarcted hearts of mice in cardiomyocytes via the TGR5-NFκB pathway [138]. In line with these results, serum DCA was reduced in acute myocardial patients [138].
FXR activation in VSMCs stimulates the angiotensin system [132][133]. FXR activation in rat aortic smooth muscle cells led to increased expression of angiotensin (Ang) II type 2 receptor (AT2R) and the inhibition of Ang II-mediated extracellular signal-regulated kinase (ERK) activation and cell proliferation [133]. Whereas angiotensin II Type I Receptor (AT1R) activation has vasopressor effects, AT2R activation has vasodilatory roles in the regulation of blood pressure [139]. These vasodilatory effects were impaired in cultured rabbit mesenteric arteries after chronic FXR activation. The FXR agonist GW4064 dose-dependently impaired endothelium relaxation, caused by the decreased sensibility of VSMCs to NO [132]. Thus, these studies suggest different roles in the regulation of blood pressure upon short- and long-term FXR activation.
Whole body FXR/SHP double knockout mice, a model of BA overload, displayed cardiac hypertrophy, bradycardia, and exercise intolerance [140]. Cardiac fatty acid oxidation was reduced in favour of glucose oxidation. Cholestatic mice also have elevated plasma BAs and show increased hypertrophic signalling in the heart, along with suppressed fatty acid oxidation and increased myocardial glycogen content [141]. Interestingly, reducing plasma BAs by intestinal BA sequestration reversed the observed heart dysfunction in FXR/SHP double knockout mice [140]. These results imply a role of serum BAs on heart function. Of note, mechanistic studies have demonstrated that only the deletion of SHP led to hypertrophy and bradycardia [140], suggesting that SHP is an important antihypertrophic regulator.
VDR signalling is also involved in regulating cardiac function [142][143]. Functional VDR is found in t-tubules of cardiac myocytes [142]. T-tubules regulate intracellular calcium flow and allow the heart to contract more forcefully [144]. Cardiac myocytes isolated from VDR knockout mice show increased rates of contraction, cardiac hypertrophy, and systolic and diastolic dysfunction compared with wild-type mice [142]. In addition, epidemiological studies have observed a link between vitamin D deficiency and CVD [145][146][147]. Vitamin D deficiency in mouse models leads to increased systolic and diastolic blood pressure, high plasma renin and decreased urinary sodium excretion, and increased atherosclerosis in the aortic arch accompanied by increased macrophage/foam cell infiltration with ER stress activation [119]. Interestingly, vitamin D supplementation improved left ventricular (LV) function and reversed LV remodelling in heart failure (HF) patients [143]. As LCA is a potent endogenous ligand of VDR in T cells, it may be speculated whether these specific BAs can also activate VDR in other cell-types, such as myocytes. If this is the case, LCA-VDR signalling in myocytes could be involved in the modulation of heart function.
BAs also bind to “non-classical BAR”, such as muscarinic (acetylcholine) receptors (MR) [11]. MRs are G-protein coupled receptors and are classified into different subtypes, namely M1R–M5R [11]. Molecular modelling shows strong similarities in the molecular surface of acetylcholine and BAs [148]. In contrast with acetylcholine, BA-specific MR activation depends on hydrophobic interactions. Hence, conjugates of (hydrophobic) secondary BAs showed favourable binding to M3R, acting as antagonists [148][149][150][151]. Tauro-LCA (TLCA) and conjugates of DCA are bound to M3R and inhibit acetylcholine-induced increases in inositol phosphate formation and MAPK phosphorylation [149][150]. Moreover, tauro-DCA (TDCA) stimulated vasodilatory actions in rat thoracic aortae rings, in part by an NO-, M3R-dependent mechanism [152]. Additionally, conjugated BAs were found to be partial agonists of M2R, slowing the contraction rate in neonatal mesenteric vascular muscle cells [153]. Tauro-CA (TCA) was found to interact with M2R on neonatal rat cardiomyocytes, lowering intracellular cAMP and inducing arrhythmia in cardiac tissue. Arrhythmia was caused by reduced myocardial cell contraction [154]. Importantly, reduced contraction could also be the consequence of cytotoxicity at higher BA concentrations [153]. The effects of BAs on the remaining MRs in the heart remain to be explored.
In addition to binding to BAR and MRs, BAs can interact with ion channels, such as the large conductance Ca2+-activated K+ (BKCa) channel [155][156] and Na+/Ca2+ exchange protein (NCX) [157]. Natural BAs and synthetic analogues show direct binding to BKCa channels, increasing their activity and leading to the relaxation of rabbit mesenteric artery smooth muscle cells [155]. For example, LCA was found to mediate BKCa channel activation causing relaxation in the small arteries [156]. Moreover, TCA dose-dependently induced arrhythmias in adult human atrial tissue, probably by depolarization of the resting membrane potential, enhancing the NCX current density, and inducing after polarizations [157]. These effects were prevented after NCX inhibition [157].
To summarize, BAs are recognized signalling molecules in modulating cardiovascular function. Their action is mediated by BARs, MRs, or ion channel interaction and mostly leads to vasodilatory effects. The hydrophobicity, polarity, and/or conjugation state of BAs seems to play an important role in the magnitude of receptor/channel activation. Future studies should uncover BA effects in cardiac tissue to exploit BA-mediated targets in order to control heart disease.

This entry is adapted from the peer-reviewed paper 10.3390/nu15081850

References

  1. Monte, M.J.; Marin, J.J.G.; Antelo, A.; Vazquez-Tato, J. Bile acids: Chemistry, physiology, and pathophysiology. World J. Gastroenterol. 2009, 15, 804–816.
  2. Russell, D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003, 72, 137–174.
  3. Ridlon, J.M.; Kang, D.J.; Hylemon, P.B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 2006, 47, 241–259.
  4. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiol. Rev. 2009, 89, 147–191.
  5. Wahlström, A.; Sayin, S.I.; Marschall, H.U.; Bäckhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016, 24, 41–50.
  6. Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 24, 678–693.
  7. Li-Hawkins, J.; Gåfvels, M.; Olin, M.; Lund, E.G.; Andersson, U.; Schuster, G.; Björkhem, I.; Russell, D.W. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Investig. 2002, 110, 1191–1200.
  8. Sayin, S.I.; Wahlström, A.; Felin, J.; Jäntti, S.; Marschall, H.U.; Bamberg, K.; Angelin, B.; Hyötyläinen, T.; Orešič, M.; Bäckhed, F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17, 225–235.
  9. Li, R.; Andreu-Sánchez, S.; Kuipers, F.; Fu, J. Gut microbiome and bile acids in obesity-related diseases. Best Pract. Res. Clin. Endocrinol. Metab. 2021, 35, 101493.
  10. Kuipers, F.; Bloks, V.W.; Groen, A.K. Beyond intestinal soap—Bile acids in metabolic control. Nat. Rev. Endocrinol. 2014, 10, 488–498.
  11. Khurana, S.; Raufman, J.P.; Pallone, T.L. Bile acids regulate cardiovascular function. Clin. Transl. Sci. 2011, 4, 210–218.
  12. Chiang, J.Y.L. Bile acid metabolism and signaling. Compr. Physiol. 2013, 3, 1191–1212.
  13. Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 2012, 53, 1723–1737.
  14. Ahmad, T.R.; Haeusler, R.A. Bile acids in glucose metabolism and insulin signalling—Mechanisms and research needs. Nat. Rev. Endocrinol. 2019, 15, 701–712.
  15. Sun, R.; Xu, C.; Feng, B.; Gao, X.; Liu, Z. Critical roles of bile acids in regulating intestinal mucosal immune responses. Ther. Adv. Gastroenterol. 2021, 14, 17562848211018098.
  16. Chen, L.; van den Munckhof, I.C.L.; Schraa, K.; ter Horst, R.; Koehorst, M.; van Faassen, M.; van der Ley, C.; Doestzada, M.; Zhernakova, D.V.; Kurilshikov, A.; et al. Genetic and Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and Liver Fat Content. Cell Rep. 2020, 33, 108212.
  17. Kim, G.B.; Miyamoto, C.M.; Meighen, E.A.; Lee, B.H. Cloning and characterization of the bile salt hydrolase genes (bsh) from Bifidobacterium bifidum strains. Appl. Environ. Microbiol. 2004, 70, 5603–5612.
  18. Coleman, J.P.; Hudson, L.L. Cloning and Characterization of a Conjugated Bile Acid Hydrolase Gene from Clostridium perfringens. Appl. Environ. Microbiol. 1995, 61, 2514–2520.
  19. Dussurget, O.; Cabanes, D.; Dehoux, P.; Lecuit, M.; Buchrieser, C.; Glaser, P.; Cossart, P.; European Listeria Genome Consortium. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol. Microbiol. 2002, 45, 1095–1106.
  20. Begley, M.; Sleator, R.D.; Gahan, C.G.M.; Hill, C. Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect. Immun. 2005, 73, 894–904.
  21. Wang, Z.; Zeng, X.; Mo, Y.; Smith, K.; Guo, Y.; Lin, J. Identification and characterization of a bile salt hydrolase from Lactobacillus salivarius for development of novel alternatives to antibiotic growth promoters. Appl. Environ. Microbiol. 2012, 78, 8795–8802.
  22. Corzo, G.; Gilliland, S.E. Bile salt hydrolase activity of three strains of Lactobacillus acidophilus. J. Dairy Sci. 1999, 82, 472–480.
  23. Stellwag, E.J.; Hylemon, P.B. Purification and characterization of bile salt hydrolase from Bacteroides fragilis subsp. fragilis. Biochim. Biophys. Acta 1976, 452, 165–176.
  24. Song, Z.; Cai, Y.; Lao, X.; Wang, X.; Lin, X.; Cui, Y.; Kalavagunta, P.K.; Liao, J.; Jin, L.; Shang, J.; et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome 2019, 7, 9.
  25. Jia, B.; Park, D.; Hahn, Y.; Jeon, C.O. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. Gut Microbes. 2020, 11, 1300–1313.
  26. Quinn, R.A.; Melnik A v Vrbanac, A.; Fu, T.; Patras, K.A.; Christy, M.P.; Bodai, Z.; Belda-Ferre, P.; Tripathi, A.; Chung, L.K.; Dorrestein, P.C.; et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature 2020, 579, 123–129.
  27. Doden, H.; Sallam, L.A.; Devendran, S.; Ly, L.; Doden, G.; Daniel, S.L.; Alves, J.M.P.; Ridlon, J.M. Metabolism of oxo-bile acids and characterization of recombinant 12α- hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. Appl. Environ. Microbiol. 2018, 84, e00235-18.
  28. Yoshimoto, S.; Loo, T.M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.; Hattori, M.; et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499, 97–101.
  29. Bernstein, C.; Holubec, H.; Bhattacharyya, A.K.; Nguyen, H.; Payne, C.M.; Zaitlin, B.; Bernstein, H. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 2011, 85, 863–871.
  30. Berr, F.; Kullak-Ublick, G.A.; Paumgartner, G.; Mu¨nzing, W.; Mu¨nzing, M.; Hylemon, P.B. 7a-Dehydroxylating Bacteria Enhance Deoxycholic Acid Input and Cholesterol Saturation of Bile in Patients With Gallstones. Gastroenterology 1996, 111, 1611–1620.
  31. Brown, J.M.; Hazen, S.L. Microbial modulation of cardiovascular disease. Nat. Rev. Microbiol. 2018, 16, 171–181.
  32. Kang, D.J.; Ridlon, J.M.; Moore, D.R.; Barnes, S.; Hylemon, P.B. Clostridium scindens baiCD and baiH genes encode stereo-specific 7α/7β-hydroxy-3-oxo-Δ4-cholenoic acid oxidoreductases. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2008, 1781, 16–25.
  33. Urdaneta, V.; Casadesús, J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front. Med. 2017, 4, 163.
  34. Hofmann, A.F.; Eckmann, L. How bile acids confer gut mucosal protection against bacteria. Proc. Natl. Acad. Sci. USA 2006, 103, 4333–4334.
  35. Ruiz, L.; Margolles, A.; Sánchez, B. Bile resistance mechanisms in Lactobacillus and Bifidobacterium. Front. Microbiol. 2013, 4, 396.
  36. Kenny, D.J.; Plichta, D.R.; Shungin, D.; Koppel, N.; Hall, A.B.; Fu, B.; Vasan, R.S.; Shaw, S.Y.; Vlamakis, H.; Balskus, E.P.; et al. Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level. Cell. Host Microbe. 2020, 28, 245–257.e6.
  37. Le, H.H.; Lee, M.T.; Besler, K.R.; Comrie, J.M.C.; Johnson, E.L. Characterization of interactions of dietary cholesterol with the murine and human gut microbiome. Nat. Microbiol. 2022, 7, 1390–1403.
  38. Yao, L.; D’Agostino, G.D.; Park, J.; Hang, S.; Adhikari, A.A.; Zhang, Y.; Li, W.; Avila-Pacheco, J.; Bae, S.; Clish, C.B.; et al. A biosynthetic pathway for the selective sulfonation of steroidal metabolites by human gut bacteria. Nat. Microbiol. 2022, 7, 1404–1418.
  39. Davidson, M.; Kuo, C.C.; Middaugh, J.P.; Campbell, L.A.; Wang, S.P.; Newman, W.P.; Finley, J.C.; Grayston, J.T. Confirmed Previous Infection With Chlamydia pneumoniae (TWAR) and Its Presence in Early Coronary Atherosclerosis. Circulation 1998, 98, 628–633.
  40. Koren, O.; Spor, A.; Felin, J.; Fåk, F.; Stombaugh, J.; Tremaroli, V.; Behre, C.J.; Knight, R.; Fagerberg, B.; Ley, R.E.; et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. S1), 4592–4598.
  41. Chakaroun, R.M.; Olsson, L.M.; Bäckhed, F. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease. Nat. Rev. Cardiol. 2022, 20, 217–235.
  42. Lanter, B.B.; Sauer, K.; Davies, D.G. Bacteria present in carotid arterial plaques are found as biofilm deposits which may contribute to enhanced risk of plaque rupture. MBio 2014, 5, e01206-14.
  43. Ott, S.J.; el Mokhtari, N.E.; Musfeldt, M.; Hellmig, S.; Freitag, S.; Rehman, A.; Kühbacher, T.; Nikolaus, S.; Namsolleck, P.; Blaut, M. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006, 113, 929–937.
  44. Verhaar, B.J.H.; Prodan, A.; Nieuwdorp, M.; Muller, M. Gut microbiota in hypertension and atherosclerosis: A review. Nutrients 2020, 12, 2982.
  45. Barlow, G.M.; Yu, A.; Mathur, R. Role of the gut microbiome in obesity and diabetes mellitus. Nutr. Clin. Pract. 2015, 30, 787–797.
  46. Tilg, H.; Moschen, A.R.; Kaser, A. Obesity and the Microbiota. Gastroenterology 2009, 136, 1476–1483.
  47. Zheng, Y.Y.; Wu, T.T.; Liu, Z.Q.; Li, A.; Guo, Q.Q.; Ma, Y.Y.; Zhang, Z.L.; Xun, Y.L.; Zhang, J.C.; Wang, W.-R.; et al. Gut Microbiome-Based Diagnostic Model to Predict Coronary Artery Disease. J. Agric. Food Chem. 2020, 68, 3548–3557.
  48. Yin, J.; Liao, S.X.; He, Y.; Wang, S.; Xia, G.H.; Liu, F.T.; Zhu, J.J.; You, C.; Chen, Q.; Zhou, L.; et al. Dysbiosis of gut microbiota with reduced trimethylamine-n-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J. Am. Heart Assoc. 2015, 4, e002699.
  49. Jie, Z.; Xia, H.; Zhong, S.L.; Feng, Q.; Li, S.; Liang, S.; Zhong, H.; Liu, Z.; Gao, Y.; Zhao, H.; et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 2017, 8, 845.
  50. Liu, H.; Chen, X.; Hu, X.; Niu, H.; Tian, R.; Wang, H.; Pang, H.; Jiang, L.; Qiu, B.; Chen, X.; et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome 2019, 7, 68.
  51. Yoshida, N.; Emoto, T.; Yamashita, T.; Watanabe, H.; Hayashi, T.; Tabata, T.; Hoshi, N.; Hatano, N.; Ozawa, G.; Sasaki, N.; et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018, 138, 2486–2498.
  52. Chong Nguyen, C.; Duboc, D.; Rainteau, D.; Sokol, H.; Humbert, L.; Seksik, P.; Bellino, A.; Abdoul, H.; Bouazza, N.; Treluyer, J.M.; et al. Circulating bile acids concentration is predictive of coronary artery disease in human. Sci. Rep. 2021, 11, 22661.
  53. Li, W.; Shu, S.; Cheng, L.; Hao, X.; Wang, L.; Wu, Y.; Yuan, Z.; Zhou, J. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis 2020, 292, 193–200.
  54. Steiner, C.; Othman, A.; Saely, C.H.; Rein, P.; Drexel, H.; von Eckardstein, A.; Rentsch, K.M. Bile acid metabolites in serum: Intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS ONE 2011, 6, e25006.
  55. Neale, G.; Lewis, B.; Weaver, V.; Panveliwalla, D. Serum bile acids in liver disease. Gut 1971, 12, 145–152.
  56. Sirtori, C.R. The pharmacology of statins. Pharmacol. Res. 2014, 88, 3–11.
  57. Li, Y.; Zhang, D.; He, Y.; Chen, C.; Song, C.; Zhao, Y.; Bai, Y.; Wang, Y.; Pu, J.; Chen, J.; et al. Investigation of novel metabolites potentially involved in the pathogenesis of coronary heart disease using a UHPLC-QTOF/MS-based metabolomics approach. Sci. Rep. 2017, 7, 15357.
  58. Charach, G.; Grosskopf, I.; Rabinovich, A.; Shochat, M.; Weintraub, M.; Rabinovich, P. The association of bile acid excretion and atherosclerotic coronary artery disease. Ther. Adv. Gastroenterol. 2011, 4, 95–101.
  59. Charach, G.; Karniel, E.; Novikov, I.; Galin, L.; Vons, S.; Grosskopf, I.; Charach, L. Reduced bile acid excretion is an independent risk factor for stroke and mortality: A prospective follow-up study. Atherosclerosis 2020, 293, 79–85.
  60. Charach, G.; Argov, O.; Geiger, K.; Charach, L.; Rogowski, O.; Grosskopf, I. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Ther. Adv. Gastroenterol. 2018, 11, 1756283X17743420.
  61. Libby, P. The changing landscape of atherosclerosis. Nature 2021, 592, 524–533.
  62. Watanabe, M.; Houten, S.M.; Wang, L.; Moschetta, A.; Mangelsdorf, D.J.; Heyman, R.A.; Moore, D.D.; Auwerx, J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Investig. 2004, 113, 1408–1418.
  63. Wiegman, C.H.; Bandsma, R.H.J.; Ouwens, M.; Van Der Sluijs, F.H.; Havinga, R.; Boer, T.; Reijngoud, D.J.; Romijn, J.A.; Kuipers, F. Hepatic VLDL Production in ob/ob Mice is Not Stimulated by Massive De Novo Lipogenesis but is Less Sensitive to the Suppressive Effects of Insulin. Diabetes 2003, 52, 1081–1089.
  64. Schoonjans, K.; Staels, B.; Auwerx’, J. I review Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 1996, 37, 907–925.
  65. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125–1131.
  66. Preidis, G.A.; Kim, K.H.; Moore, D.D. Nutrient-sensing nuclear receptors PPAR and FXR control liver energy balance. J. Clin. Investig. 2017, 127, 1193–1201.
  67. Srivastava, R.A.K.; Jahagirdar, R.; Azhar, S.; Sharma, S.; Bisgaier, C.L. Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 2006, 285, 35–50.
  68. Lee, Y.; Kim, B.R.; Kang, G.H.; Lee, G.J.; Park, Y.J.; Kim, H.; Jang, H.C.; Choi, S.H. The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice. Endocrinol. Metab. 2021, 36, 1243–1253.
  69. Torra, I.P.; Claudel, T.; Duval, C.; Kosykh, V.; Fruchart, J.C.; Staels, B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor. Mol. Endocrinol. 2003, 17, 259–272.
  70. Staudinger, J.L.; Goodwin, B.; Jones, S.A.; Hawkins-Brown, D.; Mackenzie, K.I.; Latour, A.; Liu, Y.; Klaassen, C.D.; Brown, K.K.; Reinhard, J.; et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 2001, 98, 3369–3374.
  71. Zhou, C.; King, N.; Chen, K.Y.; Breslow, J.L. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J. Lipid Res. 2009, 50, 2004–2013.
  72. Sui, Y.; Xu, J.; Rios-Pilier, J.; Zhou, C. Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J. Lipid Res. 2011, 52, 1652–1659.
  73. Park, Y.M. CD36, a scavenger receptor implicated in atherosclerosis. Exp. Mol. Med. 2014, 46, e99.
  74. Huang, K.; Liu, C.; Peng, M.; Su, Q.; Liu, R.; Guo, Z.; Chen, S.; Li, Z.; Chang, G. Glycoursodeoxycholic acid ameliorates atherosclerosis and alters gut microbiota in apolipoprotein e–deficient mice. J. Am. Heart Assoc. 2021, 10, e019820.
  75. Zurkinden, L.; Sviridov, D.; Vogt, B.; Escher, G. Downregulation of Cyp7a1 by Cholic Acid and Chenodeoxycholic Acid in Cyp27a1/ApoE Double Knockout Mice: Differential Cardiovascular Outcome. Front. Endocrinol. 2020, 11, 586980.
  76. Song, P.; Rockwell, C.E.; Cui, J.Y.; Klaassen, C.D. Individual bile acids have differential effects on bile acid signaling in mice. Toxicol. Appl. Pharmacol. 2015, 283, 57–64.
  77. Li, R.; Palmiotti, A.; de Vries, H.D.; Hovingh, M.V.; Koehorst, M.; Mulder, N.L.; Zhang, Y.; Kats, K.; Bloks, V.W.; Fu, J.; et al. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70-/- mice by reducing fat absorption. J. Lipid Res. 2021, 62, 100134.
  78. Bhat, B.G.; Rapp, S.R.; Beaudry, J.A.; Napawan, N.; Butteiger, D.N.; Hall, K.A.; Null, C.L.; Luo, Y.; Keller, B.T. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435. J. Lipid Res. 2003, 44, 1614–1621.
  79. Bishop-Bailey, D.; Walsh, D.T.; Warner, T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. USA 2004, 101, 3668–3673.
  80. Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, 272–281.
  81. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278, 9435–9440.
  82. Li, Y.T.Y.; Swales, K.E.; Thomas, G.J.; Warner, T.D.; Bishop-Bailey, D. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2606–2611.
  83. He, F.; Li, J.; Mu, Y.; Kuruba, R.; Ma, Z.; Wilson, A.; Alber, S.; Jiang, Y.; Stevens, T.; Watkins, S.; et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 2006, 98, 192–199.
  84. Pols, T.W.H.; Nomura, M.; Harach, T.; lo Sasso, G.; Oosterveer, M.H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell. Metab. 2011, 14, 747–757.
  85. Miyazaki-Anzai, S.; Masuda, M.; Kohno, S.; Levi, M.; Shiozaki, Y.; Keenan, A.L.; Miyazaki, M. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J. Lipid Res. 2018, 59, 1709–1713.
  86. Jadhav, K.; Xu, Y.; Xu, Y.; Li, Y.; Xu, J.; Zhu, Y.; Adorini, L.; Lee, Y.K.; Kasumov, T.; Yin, L.; et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol. Metab. 2018, 9, 131–140.
  87. Guo, G.L.; Santamarina-Fojo, S.; Akiyama, T.E.; Amar, M.J.A.; Paigen, B.J.; Brewer, B.; Gonzalez, F.J. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2006, 1761, 1401–1409.
  88. Zhang, Y.; Wang, X.; Vales, C.; Lee, F.Y.; Lee, H.; Lusis, A.J.; Edwards, P.A. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2316–2321.
  89. Hartman, H.B.; Gardell, S.J.; Petucci, C.J.; Wang, S.; Krueger, J.A.; Evans, M.J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. J. Lipid Res. 2009, 50, 1090–1100.
  90. Xu, Y.; Li, F.; Zalzala, M.; Xu, J.; Gonzalez, F.J.; Adorini, L.; Lee, Y.L.; Yin, L.; Zhang, Y. Farnesoid X Receptor Activation Increases Reverse Cholesterol Transport by Modulating Bile Acid Composition and Cholesterol Absorption in Mice. Hepatology 2016, 64, 1072–1085.
  91. Wu, Q.; Sun, L.; Hu, X.; Wang, X.; Xu, F.; Chen, B.; Liang, X.; Xia, J.; Wang, P.; Aibara, D.; et al. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J. Clin. Investig. 2021, 131, e143865.
  92. Tilg, H.; Zmora, N.; Adolph, T.E.; Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 2020, 20, 40–54.
  93. Frostegård, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013, 11, 117.
  94. Zhong, Z.; Zhang, H.; Xu, T.; Hao, J.; Chen, X.; Sun, S.; Yang, J.; Sun, J.; Lin, H.; Guo, H. Identification and verification of immune-related biomarkers and immune infiltration in diabetic heart failure. Front. Cardiovasc. Med. 2022, 9, 931066.
  95. Hayward, S.L.; Bautista-Lopez, N.; Suzuki, K.; Atrazhev, A.; Dickie, P.; Elliott, J.F. CD4 T Cells Play Major Effector Role and CD8 T Cells Initiating Role in Spontaneous Autoimmune Myocarditis of HLA-DQ8 Transgenic IAb Knockout Nonobese Diabetic Mice 1. J. Immunol. 2006, 176, 7715–7725.
  96. Kumar, V.; Prabhu, S.D.; Bansal, S.S. CD4+ T-lymphocytes exhibit biphasic kinetics post-myocardial infarction. Front. Cardiovasc. Med. 2022, 9, 992653.
  97. Lu, Y.; Xia, N.; Cheng, X. Regulatory T Cells in Chronic Heart Failure. Front. Immunol. 2021, 12, 732794.
  98. Rurik, J.G.; Aghajanian, H.; Epstein, J.A. Immune Cells and Immunotherapy for Cardiac Injury and Repair. Circ. Res. 2021, 128, 1766–1779.
  99. Rosenzweig, R.; Kumar, V.; Gupta, S.; Bermeo-Blanco, O.; Stratton, M.S.; Gumina, R.J.; Bansal, S.S. Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling during Chronic Heart Failure. Circ. Heart Fail. 2022, 15, E008997.
  100. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131.
  101. Guan, B.; Tong, J.; Hao, H.; Yang, Z.; Chen, K.; Xu, H.; Wang, A. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm. Sin. B 2022, 12, 2129–2149.
  102. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.L.; Renooij, W.; Murzilli, S.; Klomp, L.W.J.; Siersema, P.D.; Schipper, M.E.I.; Danese, S.; et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60, 463–472.
  103. Sorribas, M.; Jakob, M.O.; Yilmaz, B.; Li, H.; Stutz, D.; Noser, Y.; de Gottardi, A.; Moghadamrad, S.; Hassan, M.; Albillos, A.; et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J. Hepatol. 2019, 71, 1126–1140.
  104. Úbeda, M.; Lario, M.; Muñoz, L.; Borrero, M.J.; Rodríguez-Serrano, M.; Sánchez-Díaz, A.M.; Del Campo, R.; Lledó, L.; Pastor, Ó.; García-Bermejo, L.; et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 2016, 64, 1049–1057.
  105. Inagaki, T.; Moschetta, A.; Lee, Y.K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. USA 2006, 103, 3920–3925.
  106. Yao, B.; He, J.; Yin, X.; Shi, Y.; Wan, J.; Tian, Z. The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells. Toxicol. Lett. 2019, 316, 109–118.
  107. Hang, S.; Paik, D.; Yao, L.; Kim, E.; Jamma, T.; Lu, J.; Ha, S.; Nelson, B.N.; Kelly, S.P.; Wu, L.; et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature 2019, 576, 143–148.
  108. Qin, P.; Tang, X.; Elloso, M.M.; Harnish, D.C. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-B, and p38. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, 741–747.
  109. Lu, S.; Guo, S.; Hu, F.; Guo, Y.; Yan, L.; Ma, W.; Wang, Y.; Wei, Y.; Zhang, Z.; Wang, Z.; et al. The associations between the polymorphisms of Vitamin D receptor and coronary artery disease. Medicine 2016, 95, e3467.
  110. Szeto, F.L.; Reardon, C.A.; Yoon, D.; Wang, Y.; Wong, K.E.; Chen, Y.; Kong, J.; Liu, S.Q.; Thadhani, R.; Getz, G.S.; et al. Vitamin D receptor signaling inhibits atherosclerosis in Mice. Mol. Endocrinol. 2012, 26, 1091–1101.
  111. Latic, N.; Erben, R.G. Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. Int. J. Mol. Sci. 2020, 21, 6483.
  112. Stenman, L.K.; Holma, R.; Eggert, A.; Korpela, R. A novel mechanism for gut barrier dysfunction by dietary fat: Epithelial disruption by hydrophobic bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304, 227–234.
  113. Zhao, S.; Gong, Z.; Du, X.; Tian, C.; Wang, L.; Zhou, J.; Xu, C.; Chen, Y.; Cai, W.; Wu, J. Deoxycholic acid-mediated sphingosine-1-phosphate receptor 2 signaling exacerbates DSS-induced colitis through promoting cathepsin b release. J. Immunol. Res. 2018, 2018, 2481418.
  114. Wang, L.; Gong, Z.; Zhang, X.; Zhu, F.; Liu, Y.; Jin, C.; Du, X.; Xu, C.; Chen, Y.; Cai, W.; et al. Gut microbial bile acid metabolite skews macrophage polarization and contributes to high-fat diet-induced colonic inflammation. Gut Microbes 2020, 12, 1819155.
  115. Wang, J.; Xu, T.; Xu, M. Roles and Mechanisms of TGR5 in the Modulation of CD4+ T Cell Functions in Myocardial Infarction. J. Cardiovasc. Transl. Res. 2022, 15, 350–359.
  116. Guo, C.; Xie, S.; Chi, Z.; Zhang, J.; Liu, Y.; Zhang, L.; Zheng, M.; Zhang, X.; Xia, D.; Ke, Y.; et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity 2016, 45, 802–816.
  117. Yang, C.S.; Kim, J.J.; Kim, T.S.; Lee, P.Y.; Kim, S.Y.; Lee, H.M.; Shin, D.M.; Nguyen, L.T.; Lee, M.S.; Jin, H.S.; et al. Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome. Nat. Commun. 2015, 6, 6115.
  118. Oh, J.; Riek, A.E.; Darwech, I.; Funai, K.; Shao, J.S.; Chin, K.; Sierra, O.L.; Carmeliet, G.; Ostlund, R.E.; Bernal-Mizrachi, C. Deletion of macrophage vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. Cell. Rep. 2015, 10, 1872–1886.
  119. Weng, S.; Sprague, J.E.; Oh, J.; Riek, A.E.; Chin, K.; Garcia, M.; Bernal-Mizrachi, C. Vitamin D Deficiency Induces High Blood Pressure and Accelerates Atherosclerosis in Mice. PLoS ONE 2013, 8, e54625.
  120. Dong, B.; Zhou, Y.; Wang, W.; Scott, J.; Kim, K.; Sun, Z.; Guo, Q.; Lu, Y.; Gonzales, N.M.; Wu, H.; et al. Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice. Hepatology 2020, 71, 1559–1574.
  121. Chen, P.B.; Black, A.S.; Sobel, A.L.; Zhao, Y.; Mukherjee, P.; Molparia, B.; Moore, N.E.; Aleman Muench, G.R.; Wu, J.; Chen, W.; et al. Directed remodeling of the mouse gut microbiome inhibits the development of atherosclerosis. Nat. Biotechnol. 2020, 38, 1288–1297.
  122. Liu, H.; Tian, R.; Wang, H.; Feng, S.; Li, H.; Xiao, Y.; Luan, X.; Zhang, Z.; Shi, N.; Niu, H.; et al. Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation. J. Transl. Med. 2020, 18, 382.
  123. Brandsma, E.; Kloosterhuis, N.J.; Koster, M.; Dekker, D.C.; Gijbels, M.J.; van der Velden, S.; Ríos-Morales, M.; van Faassen, M.J.; Loreti, M.G.; de Bruin, A.; et al. A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis. Circ. Res. 2019, 124, 94–100.
  124. Schiering, C.; Krausgruber, T.; Chomka, A.; Fröhlich, A.; Adelmann, K.; Wohlfert, E.A.; Pott, J.; Griseri, T.; Bollrath, J.; Hegazy, A.N.; et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014, 513, 564–568.
  125. Binder, C.J.; Hörkkö, S.; Dewan, A.; Chang, M.K.; Kieu, E.P.; Goodyear, C.S.; Silverman, G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 2003, 9, 736–743.
  126. Paik, D.; Yao, L.; Zhang, Y.; Bae, S.; D’Agostino, G.D.; Zhang, M.; Kim, E.; Franzosa, E.A.; Avila-Pacheco, J.; Bisanz, J.E.; et al. Human gut bacteria produce ΤH17-modulating bile acid metabolites. Nature 2022, 603, 907–912.
  127. Li, W.; Hang, S.; Fang, Y.; Bae, S.; Zhang, Y.; Zhang, M.; Wang, G.; McCurry, M.D.; Bae, M.; Paik, D.; et al. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell. Host Microbe. 2021, 29, 1366–1377.e9.
  128. Song, X.; Sun, X.; Oh, S.F.; Wu, M.; Zhang, Y.; Zheng, W.; Geva-Zatorsky, N.; Jupp, R.; Mathis, D.; Benoist, C.; et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature 2020, 577, 410–415.
  129. Campbell, C.; McKenney, P.T.; Konstantinovsky, D.; Isaeva, O.I.; Schizas, M.; Verter, J.; Mai, C.; Jin, W.B.; Guo, C.J.; Violante, S.; et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 2020, 581, 475–479.
  130. Lahore, G.F.; Raposo, B.; Lagerguist, M.; Ohlsson, C.; Sabatier, P.; Xu, B.; Aoun, M.; James, J.; Cai, X.; Zubarev, R.A.; et al. VDR polymorphisms regulated t cells and t cell dependent inflammatory disease. Proc. Natl. Acad. Sci. USA 2020, 117, 24986–24997.
  131. Pu, J.; Yuan, A.; Shan, P.; Gao, E.; Wang, X.; Wang, Y.; Lau, W.B.; Koch, W.; Ma, X.L.; He, B. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur. Heart J. 2013, 34, 1834–1845.
  132. Kida, T.; Murata, T.; Hori, M.; Ozaki, H. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H195–H201.
  133. Zhang, Q.; He, F.; Kuruba, R.; Gao, X.; Wilson, A.; Li, J.; Billiar, T.J.; Pitt, B.R.; Xie, W.; Li, S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc. Res. 2008, 77, 560–569.
  134. Li, J.; Wilson, A.; Kuruba, R.; Zhang, Q.; Gao, X.; He, F.; Zhang, L.M.; Pitt, B.R.; Xie, W.; Li, S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 2008, 77, 169–177.
  135. Rajesh, K.G.; Suzuki, R.; Maeda, H.; Yamamoto, M.; Yutong, X.; Sasaguri, S. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway. J. Mol. Cell. Cardiol. 2005, 39, 766–776.
  136. Thromb, A.; Biol, V. Bile Acid Receptor TGR5 Agonism Induces NO Production and Reduces Monocyte Adhesion in Vascular Endothelial Cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1663–1669.
  137. Sandoo, A.; Veldhuijzen Van Zanten, J.J.C.S.; Metsios, G.S.; Carroll, D.; Kitas, G.D. The Endothelium and Its Role in Regulating Vascular Tone. Open Cardiovasc. Med. J. 2010, 4, 302–312.
  138. Wang, J.; Zhang, J.; Lin, X.; Wang, Y.; Wu, X.; Yang, F.; Gao, W.; Zhang, Y.; Sun, J.; Jiang, C.; et al. DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction. J. Mol. Cell. Cardiol. 2021, 151, 3–14.
  139. Mehta, P.K.; Griendling, K.K.; Griendling, K.K. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell. Physiol. 2007, 292, 82–97.
  140. Desai, M.S.; Mathur, B.; Eblimit, Z.; Vasquez, H.; Taegtmeyer, H.; Karpen, S.J.; Penny, D.J.; Moore, D.D.; Anakk, S. Bile Acid Excess Induces Cardiomyopathy and Metabolic Dysfunctions in the Heart. Hepatology 2017, 65, 189–201.
  141. Desai, M.S.; Shabier, Z.; Taylor, M.; Lam, F.; Thevananther, S.; Kosters, A.; Karpen, S.J. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 2010, 51, 2097–2107.
  142. Tishkoff, D.X.; Nibbelink, K.A.; Holmberg, K.H.; Dandu, L.; Simpson, R.U. Functional vitamin D receptor (VDR) in the T-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008, 149, 558–564.
  143. Rodriguez, A.J.; Mousa, A.; Ebeling, P.R.; Scott, D.; de Courten, B. Effects of Vitamin D supplementation on inflammatory markers in heart failure: A systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 2018, 8, 1169.
  144. Ibrahim, M.; Gorelik, J.; Yacoub, M.H.; Terracciano, C.M. The structure and function of cardiac t-tubules in health and disease. Proc. R. Soc. B Biol. Sci. 2011, 278, 2714–2723.
  145. Giovannucci, E.; Liu, Y.; Hollis, B.W.; Rimm, E.B. 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men a Prospective Study. Arch. Intern. Med. 2008, 168, 1174–1180.
  146. Dobnig, H.; Pilz, S.; Scharnagl, H.; Renner, W.; Seelhorst, U.; Wellnitz, B.; Kinkeldei, J.; Boehm, B.O.; Weihrauch, G.; Maerz, W. Independent Association of Low Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels With All-Cause and Cardiovascular Mortality. Arch. Intern. Med. 2008, 168, 1340–1349.
  147. Wang, T.J.; Pencina, M.J.; Booth, S.L.; Jacques, P.F.; Ingelsson, E.; Lanier, K.; Benjamin, E.J.; D’Agostino, R.B.; Wolf, M.; Vasan, R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117, 503–511.
  148. Raufman, J.P.; Chen, Y.; Cheng, K.; Compadre, C.; Compadre, L.; Zimniak, P. Selective interaction of bile acids with muscarinic receptors: A case of molecular mimicry. Eur. J. Pharmacol. 2002, 457, 77–84.
  149. Raufman, J.P.; Chen, Y.; Zimniak, P.; Cheng, K. Deoxycholic Acid Conjugates are Muscarinic Cholinergic Receptor Antagonists. Pharmacology 2002, 65, 215–221.
  150. Cheng, K.; Khurana, S.; Chen, Y.; Kennedy, R.H.; Zimniak, P.; Raufman, J.P. Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J. Pharmacol. Exp. Ther. 2002, 303, 29–35.
  151. Shah, N.; Khurana, S.; Cheng, K.; Raufman, J.P. Muscarinic receptors and ligands in cancer. Am. J. Physiol. Cell. Physiol. 2009, 296, 221–232.
  152. Khurana, S.; Yamada, M.; Wess, J.; Kennedy, R.H.; Raufman, J.P. Deoxycholyltaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M3 receptor-dependent. Eur. J. Pharmacol. 2005, 517, 103–110.
  153. Ibrahim, E.; Diakonov, I.; Arunthavarajah, D.; Swift, T.; Goodwin, M.; McIlvride, S.; Nikolova, V.; Williamson, C.; Gorelik, J. Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: Role of Gi protein, muscarinic receptors and TGR5. Sci. Rep. 2018, 8, 7110.
  154. Sheikh Abdul Kadir, S.H.; Miragoli, M.; Abu-Hayyeh, S.; Moshkov A v Xie, Q.; Keitel, V.; Nikolaev, V.O.; Williamson, C.; Gorelik, J. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS ONE 2010, 5, e9689.
  155. Dopico, A.M.; Walsh J v Singer, J.J. Natural Bile Acids and Synthetic Analogues Modulate Large Conductance Ca 2-activated K (BK Ca) Channel Activity in Smooth Muscle Cells. J. Gen. Physiol. 2002, 119, 251–273.
  156. Bukiya, A.N.; Liu, J.; Toro, L.; Dopico, A.M. β1 (KCNMB1) subunits mediate lithocholate activation of large-conductance Ca2+-activated K+ channels and dilation in small, resistance-size arteries. Mol. Pharmacol. 2007, 72, 359–369.
  157. Rainer, P.P.; Primessnig, U.; Harenkamp, S.; Doleschal, B.; Wallner, M.; Fauler, G.; Stojakovic, T.; Wachter, R.; Yates, A.; Groschner, K.; et al. Bile acids induce arrhythmias in human atrial myocardium-implications for altered serum bile acid composition in patients with atrial fibrillation. Heart 2013, 99, 1685–1692.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback